Humacyte (NASDAQ:HUMA – Get Free Report) was upgraded by stock analysts at Wall Street Zen to a “sell” rating in a research report issued on Saturday, Wall Street Zen reports.
A number of other equities analysts also recently issued reports on HUMA. Barclays raised their price objective on Humacyte from $0.50 to $0.60 and gave the stock an “equal weight” rating in a research report on Wednesday, November 11th. Williams Trading set a $1.00 price objective on Humacyte in a research note on Friday, October 16th. HC Wainwright reiterated a “buy” rating on shares of Humacyte in a report on Friday, October 16th. BTIG Research reissued a “buy” rating and set a $2.00 target price on shares of Humacyte in a research report on Tuesday, November 10th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Humacyte in a report on Friday, October 2nd. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Humacyte has a consensus rating of “Moderate Buy” and an average price target of $4.48.
Get Our Latest Report on Humacyte
Humacyte Price Performance
Institutional Investors Weigh In On Humacyte
Hedge funds and other institutional investors have recently modified their holdings of the company. Alyeska Investment Group L.P. bought a new position in shares of Humacyte in the second quarter valued at $4,700,000. BlackRock Inc. acquired a new position in shares of Humacyte during the second quarter valued at about $3,777,000. Marshall Wace LLP increased its position in shares of Humacyte by 1,548.0% during the third quarter. Marshall Wace LLP now owns 2,996,553 shares of the company’s stock worth $1,558,000 after acquiring an additional 2,814,722 shares in the last quarter. GSA Capital Partners LLP bought a new stake in shares of Humacyte during the second quarter worth about $785,000. Finally, Private Advisor Group LLC bought a new stake in shares of Humacyte during the third quarter worth about $491,000. Institutional investors own 44.71% of the company’s stock.
More Humacyte News
These are some of the HUMA news items that stood out recently:
- Positive Sentiment: HC Wainwright raised its estimated loss per share for FY2026 to $0.39 from $0.46, and narrowed its projected losses for Q4 2026 and Q1 2027. The firm maintained its Buy rating.
- Positive Sentiment: StoneX reiterated its Speculative Buy rating, while a separate roundup highlighted Humacyte among healthcare stocks with bullish analyst views. StoneX Reiterates Speculative Buy Rating on Humacyte Analysts Are Bullish on These Healthcare Stocks
- Negative Sentiment: HC Wainwright trimmed estimates for FY2027 and FY2028, and lowered projected Q3 and Q4 2027 results. It now expects a $0.31-per-share loss in FY2027 and a $0.11 loss in FY2028, signaling a slower path to profitability than previously forecast.
About Humacyte
Humacyte, Inc. is a biotechnology company developing bioengineered human tissues for vascular repair and other medical applications. Its technology uses human vascular cells to create vessels that are processed to remove the cells, leaving an acellular structure designed for implantation. The company’s lead product, Symvess, is an acellular tissue-engineered vessel for treating extremity arterial injuries in adults when a patient’s own vein cannot be used for surgical revascularization. The U.S. Food and Drug Administration approved Symvess in December 2024.
See Also
- Five stocks we like better than Humacyte
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Humacyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humacyte and related companies with MarketBeat.com's FREE daily email newsletter.
